Related Experiment Video
Updated: Jul 20, 2026
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
Platelet mass has prognostic value in patients with myelodysplastic syndromes
Kristian M Bowles1, Brian A Warner, Trevor P Baglin
1Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.
Abstract:
Platelet mass (mean platelet volume x platelet count) can be derived from data obtained from the routine full blood count and separates patients with myelodysplastic syndromes (MDS) at diagnosis into three distinct prognostic groups: low platelet mass group - median survival 5 months and 5-year survival 0%; intermediate platelet mass group - median survival 30 months and 5-year survival 34%; high platelet mass group median survival - not reached at 82 months follow-up with a 5-year survival of 82%. These data provide a simple rapid prognostic index at the time of diagnosis in MDS.
Insights
Platelet mass, calculated from routine blood counts, effectively categorizes patients with myelodysplastic syndromes (MDS) into prognostic groups. This simple index aids in predicting survival outcomes at diagnosis for MDS patients.
Area of Science:
- Hematology
- Oncology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Accurate prognostic markers are crucial for managing MDS patients.
Purpose of the Study:
- To evaluate platelet mass as a prognostic index in patients diagnosed with myelodysplastic syndromes.
- To determine if platelet mass can stratify MDS patients into distinct survival groups.
Main Methods:
- Platelet mass was calculated by multiplying mean platelet volume (MPV) by platelet count (PLT).
- Data were derived from routine full blood count (FBC) results at diagnosis.
- Patients were stratified into low, intermediate, and high platelet mass groups.
Main Results:
- Low platelet mass group: median survival 5 months, 5-year survival 0%.
- Intermediate platelet mass group: median survival 30 months, 5-year survival 34%.
- High platelet mass group: median survival not reached (82 months follow-up), 5-year survival 82%.
Conclusions:
- Platelet mass is a simple, rapid, and effective prognostic index for myelodysplastic syndromes at diagnosis.
- This index stratifies MDS patients into distinct prognostic categories, aiding clinical decision-making.
- Routine full blood count data can be utilized for improved MDS prognostication.
